Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells. Over the last few years, a number of agents have been launched that have improved treatment outcomes for patients with ALL, including monoclonal antibodies to CD19 (Amgen’s Blincyto) and CD22 (Pfizer’s Besponsa); and the first chimeric antigen receptor (CAR) T-cells for relapsed/refractory pediatric and young adult ALL patients, namely Novartis’ Kymriah. Nonetheless, chemotherapies are highly effective and remain the backbone of frontline ALL treatment. New targeted therapies in development, including novel kinase inhibitors, proteasome inhibitors, and immunomodulatory agents hold promise of providing ALL patients additional treatment options, but will need to be incorporated into the current algorithm.

Questions Answered:

  • What is the size of the U.S. and EU5ALL patient populations, and how will drug treatment rates change over a 10-year period? What are the drug-treatable populations of most commercial interest?
  •  What is the current medical practice and management for ALL in the markets under study? What are interviewed experts’ insights on CAR T-cells and how are they being incorporated into the treatment algorithm?
  • What clinical needs remain unfulfilled? How could new emerging therapies fulfill those unmet needs?
  •  How has the entry of biosimilar rituximab in the EU5 and the generic entry of imatinib in the U.S. and EU5 impacted the ALL market?

Scope:

Market covered: United States, France, Germany, Italy, Spain, and the United Kingdom.

Primary research: Six country-specific interviews with thought leaders (medical oncologist-hematologists).

Epidemiology: Diagnosed incident cases of ALL subpopulations; clinical and market-relevant drug-treatable populations.

Population segments in market forecast: First-line adult and pediatric ALL; relapsed/refractory adult and pediatric ALL.

Emerging therapies: Phase III: 3 drugs; Phase II: 2 drugs.

Product Description: Niche & Rare Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Acute Lymphoblastic Leukemia - Landscape & Forecast - Disease Landscape & Forecast
    • Commercial Outlook
      • Key Findings
        • Regional Sales of Key Therapies to Treat Acute Lymphoblastic Leukemia: 2017 and 2027
        • Population Positioning of Therapies in Acute Lymphoblastic Leukemia
        • Acute Lymphoblastic Leukemia SWOT
      • Drivers and Constraints
        • What Factors Are Driving Sales in Acute Lymphoblastic Leukemia?
        • What Factors Are Constraining Sales in Acute Lymphoblastic Leukemia?
      • Drug-Class-Specific Trends
        • Increasing Adoption of Immunotherapies
    • Forecast
      • Sales of Key Therapies in Acute Lymphoblastic Leukemia
    • Etiology and Pathophysiology
      • Disease Overview
        • Etiology
          • Disease Pathophysiology
            • Disease Classification
              • WHO Disease Classification
              • 2016 WHO Classification of Acute Lymphoblastic Leukemia
              • Immunophenotypes of Acute Lymphoblastic Leukemia
              • Immunophenotypes of Acute Lymphoblastic Leukemia
              • Prognostic Factors
              • Prognostic Factors for Acute Lymphoblastic Leukemia
              • Risk Classification of Acute Lymphoblastic Leukemia
              • Risk Classification of Adult Acute Lymphoblastic Leukemia
              • Risk Classification of Pediatric Acute Lymphoblastic Leukemia
            • Key Pathways and Drug Targets
            • Epidemiology Overview
              • Key Findings
                • Epidemiology Populations
                  • Disease Definition
                  • Methods
                  • Sources Used for Diagnosed Incident Cases of Acute Lymphoblastic Leukemia
                  • Diagnosed Incident Cases of Acute Lymphoblastic Leukemia: 2017-2027
                  • Disease Definition
                  • Methods
                  • Sources Used for Age Distribution of Diagnosed Incident Cases of Acute Lymphoblastic Leukemia
                  • Diagnosed Incident Cases of Acute Lymphoblastic Leukemia by Age Distribution: 2017-2027
                  • Acute Lymphoblastic Leukemia Patient Flow
                  • Sources Used for Drug-Treatable Populations of Acute Lymphoblastic Leukemia
                  • Drug-Treatable Cases of Acute Lymphoblastic Leukemia: 2017-2027
                  • Sources Used for Drug-Treated Populations of Acute Lymphoblastic Leukemia
                  • Drug-Treated Cases of Acute Lymphoblastic Leukemia: 2017-2027
              • Current Treatment Overview
                • Key Findings
                  • Diagnosis
                    • Treatment Providers and Referral Patterns
                  • Treatment Goals
                    • Key End Points Used in Clinical Trials for Acute Lymphoblastic Leukemia
                  • Key Current Therapies
                    • Overview
                    • Mechanism of Action of Key Current Drug Classes Used for Acute Lymphoblastic Leukemia
                    • Current Treatments Used for Acute Lymphoblastic Leukemia
                    • Population Positioning of Current Therapies in Acute Lymphoblastic Leukemia
                    • Clinical Trial Outcomes for Gleevec/Glivec
                    • Key Results from Select Clinical Trials Investigating Gleevec/Glivec for the Treatment of Acute Lymphoblastic Leukemia
                    • Key Ongoing Clinical Trials of Gleevec/Glivec in the Treatment of Acute Lymphoblastic Leukemia
                    • Clinical Trial Outcomes for Sprycel
                    • Key Results from Select Clinical Trials Investigating Sprycel for the Treatment of Acute Lymphoblastic Leukemia
                    • Key Ongoing Clinical Trials of Sprycel in the Treatment of Acute Lymphoblastic Leukemia
                    • Expert Insight: Sprycel
                    • Clinical Trial Outcomes for Iclusig
                    • Key Results from Select Clinical Trials Investigating Iclusig for the Treatment of Acute Lymphoblastic Leukemia
                    • Key Ongoing Clinical Trials of Iclusig in the Treatment of Acute Lymphoblastic Leukemia
                    • Clinical Trial Outcomes for Tasigna
                    • Key Results from Select Clinical Trials Investigating Tasigna for the Treatment of Acute Lymphoblastic Leukemia
                    • Ongoing Clinical Development
                    • Key Ongoing Clinical Trials of Tasigna in the Treatment of Acute Lymphoblastic Leukemia
                    • Clinical Trial Outcomes for Rituxan/MabThera
                    • Key Results from Select Clinical Trials Investigating Rituxan/MabThera for the Treatment of Acute Lymphoblastic Leukemia
                    • Ongoing Clinical Development
                    • Expert Insight: Rituxan/MabThera
                    • Clinical Trial Outcomes for Blincyto
                    • Key Results from Select Clinical Trials Investigating Blincyto for the Treatment of Acute Lymphoblastic Leukemia
                    • Ongoing Clinical Development
                    • Key Ongoing Clinical Trials of Blincyto in the Treatment of Acute Lymphoblastic Leukemia
                    • Expert Insight: Blincyto
                    • Clinical Trial Outcomes for Besponsa
                    • Key Results from Select Clinical Trials Investigating Besponsa for the Treatment of Acute Lymphoblastic Leukemia
                    • Ongoing Clinical Development
                    • Key Ongoing Clinical Trials of Besponsa in the Treatment of Acute Lymphoblastic Leukemia
                    • Expert Insight: Besponsa
                    • Clinical Trial Outcomes for Clolar/Evoltra
                    • Key Ongoing Clinical Trials of Clolar/Evoltra in the Treatment of Acute Lymphoblastic Leukemia
                    • Expert Insight: Clolar/Evoltra
                    • Clinical Trial Outcomes for Arranon/Atriance
                    • Key Results from Select Clinical Trials Investigating Arranon/Atriance for the Treatment of Acute Lymphoblastic Leukemia
                    • Key Ongoing Clinical Trials of Arranon/Atriance in the Treatment of Acute Lymphoblastic Leukemia
                    • Expert Insight: Arranon/Atriance
                    • Clinical Trial Outcomes for Marqibo
                    • Key Results from Select Clinical Trials Investigating Marqibo for the Treatment of Acute Lymphoblastic Leukemia
                    • Expert Insight: Marqibo
                    • Clinical Trial Outcomes for Oncaspar
                    • Key Ongoing Clinical Trials of Oncaspar in the Treatment of Acute Lymphoblastic Leukemia
                    • Expert Insight: Oncaspar
                    • Clinical Trial Outcomes for Kymriah
                    • Key Results from Select Clinical Trials Investigating Kymriah for the Treatment of Acute Lymphoblastic Leukemia
                    • Kymriah Clinical Development
                    • Key Ongoing Clinical Trials of Kymriah in the Treatment of Acute Lymphoblastic Leukemia
                    • Expert Insight: Kymriah
                  • Medical Practice
                    • Newly Diagnosed Acute Lymphoblastic Leukemia
                    • Relapsed/Refractory Acute Lymphoblastic Leukemia
                    • Regional Acute Lymphoblastic Leukemia Treatment Guidelines
                    • Patient Characteristics Influencing Drug Selection in Acute Lymphoblastic Leukemia
                    • United States and Europe
                    • Generalized Treatment Decision Tree for Pediatric Acute Lymphoblastic Leukemia
                    • Generalized Treatment Decision Tree for Adolescent and Young Adult Acute Lymphoblastic Leukemia
                    • Generalized Treatment Decision Tree for Older Adult Acute Lymphoblastic Leukemia
                • Unmet Need Overview
                  • Current and Future Attainment of Unmet Needs in Acute Lymphoblastic Leukemia
                  • Top Unmet Needs in Acute Lymphoblastic Leukemia: Current and Future Attainment
                  • Expert Insight: Unmet Needs in Acute Lymphoblastic Leukemia
                • Emerging Therapies
                  • Key Findings
                    • Pipeline Trends for Acute Lymphoblastic Leukemia
                  • Key Emerging Therapies
                    • Notable Developments Among Key Emerging Therapies for Acute Lymphoblastic Leukemia
                    • Key Therapies in Development for Acute Lymphoblastic Leukemia
                    • Estimated Market Authorization Dates of Key Emerging Therapies for the Treatment of Acute Lymphoblastic Leukemia
                    • Population Positioning of Emerging Therapies in Acute Lymphoblastic Leukemia
                    • Key Results from Select Clinical Trials Investigating Yescarta for the Treatment of Acute Lymphoblastic Leukemia
                    • Key Ongoing Clinical Trials of Yescarta in Acute Lymphoblastic Leukemia
                    • Analysis of the Clinical Development Program for Yescarta
                    • Expectations for Market Authorization and Sales Opportunity of Yescarta in Acute Lymphoblastic Leukemia
                    • Key Results from Select Clinical Trials Investigating Epratuzumab for the Treatment of Acute Lymphoblastic Leukemia
                    • Key Ongoing Clinical Trials of Epratuzumab in Acute Lymphoblastic Leukemia
                    • Analysis of the Clinical Development Program for Epratuzumab
                    • Expert Insight: Epratuzumab
                    • Expectations for Market Authorization and Sales Opportunity of Epratuzumab in Acute Lymphoblastic Leukemia
                    • Jakafi/Jakavi Profile
                    • Key Ongoing Clinical Trials for Jakafi/Jakavi in Acute Lymphoblastic Leukemia
                    • Analysis of the Clinical Development Program for Jakafi/Jakavi
                    • Expert Insight: Jakavi/Jakafi
                    • Expectations for Market Authorization and Sales Opportunity of Jakavi/Jakafi in Acute Lymphoblastic Leukemia
                    • Key Results from Select Clinical Trials Investigating Velcade for the Treatment of Acute Lymphoblastic Leukemia
                    • Key Ongoing Clinical Trials of Velcade in Acute Lymphoblastic Leukemia
                    • Analysis of the Clinical Development Program for Velcade
                    • Expectations for Market Authorization and Sales Opportunity of Velcade in Acute Lymphoblastic Leukemia
                    • Key Results from Select Clinical Trials Investigating Calaspargase Pegol for the Treatment of Acute Lymphoblastic Leukemia
                    • Key Ongoing Clinical Trials for Calaspargase Pegol in Acute Lymphoblastic Leukemia
                    • Analysis of the Clinical Development Program for Calaspargase Pegol
                    • Expectations for Market Authorization and Sales Opportunity of Calaspargase Pegol in Acute Lymphoblastic Leukemia
                  • Early-Phase Pipeline Analysis
                    • Notable Developments in the Early-Phase Pipeline for Acute Lymphoblastic Leukemia
                    • Select Compounds in Early-Phase Development for Acute Lymphoblastic Leukemia
                  • Orphan-Drug Designation
                  • Access & Reimbursement Overview
                    • Looking for More?
                    • Region-Specific Reimbursement Practices
                      • Key Market Access Considerations in Acute Lymphoblastic Leukemia: United States
                      • General Reimbursement Environment: United States
                      • Key Market Access Considerations in Acute Lymphoblastic Leukemia: EU5
                      • General Reimbursement Environment: EU5
                  • Methodology
                    • Bottom-Up Forecasting Overview
                      • Patient Populations
                      • Drug- and Regimen-Specific Assumptions
                    • Bottom-Up Forecast Assumptions
                      • General Sources of Data
                      • Drug-Treatment Rate Assumptions in Acute Lymphoblastic Leukemia
                      • Patient-Share Assumptions in Acute Lymphoblastic Leukemia
                      • General Statements About Pricing
                      • Sources for Drug Prices
                      • 2017 Exchange Rates
                      • Price per Cycle and Course Assumptions: 2017
                      • Price per Cycle and Course Assumptions: 2027
                      • Generic Erosion
                      • Generic Erosion Assumptions
                      • Biosimilar Erosion
                      • Biosimilar Erosion Assumptions
                      • Out-Year Forecasting
                      • Emerging Therapy Prices
                    • Primary Market Research
                      • Experts Interviewed
                  • Appendix
                    • Key Abbreviations Related to Acute Lymphoblastic Leukemia
                    • Brands, Marketers, and Generic Availability of Key Therapies for Acute Lymphoblastic Leukemia, by Market
                    • Acute Lymphoblastic Leukemia Bibliography

                Author(s): Amy Yip, PhD

                Amy Yip, Ph.D., is a Business Insights Analyst in the oncology team at Decision Resources Group. Prior to joining DRG, Dr. Yip worked as an analyst at GlobalData where she worked on a number of disease reports within Healthcare and Pharmaceuticals, with a particular focus on oncology. Dr. Yip obtained her doctorate in molecular medicine at the Liggins Institute, University of Auckland, where she investigated the impact of aberrant neurotrophic factor expression on hormone signaling pathways in breast cancer cells. Dr. Yip also holds a BSc (Hons) degree, with first class honors in biomedical science, awarded by the University of Auckland, and has previously worked with Novartis in their New Zealand office.


                Related Reports

                Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Janssen Proprietary Content

                In this project, comissioned by Janssen in December, 2018, we have packaged our published estimates on the epidemiology of CLL - drug treated population across all the countries in Latin Ameri...

                View Details